Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Logirène is a fixed-dose combination of two diuretics, furosemide and amiloride hydrochloride, used for the treatment of edema associated with congestive heart failure. Furosemide is a potent loop diuretic that inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, promoting the excretion of sodium, chloride, and water. Amiloride is a potassium-sparing diuretic that blocks the epithelial sodium channel (ENaC) in the late distal tubule and collecting duct, reducing sodium reabsorption while conserving potassium. This combination provides rapid and prolonged diuresis while minimizing the risk of hypokalemia, a common side effect of loop diuretics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amiloride + furosemide.